ENDOPROST 0,05MG/0,5ML 1F ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
51全身性強皮症1

51. 全身性強皮症


臨床試験数 : 525 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-002712-28-IT
(EUCTR)
28/02/200515/02/2006Chronic iloprost administration in scleroderma patients effect on disease progression, as assessed by skin fibrosis evaluation. A randomized, controlled, blind-observer, multicenter phase III study.Chronic iloprost administration in scleroderma patients effect on disease progression, as assessed by skin fibrosis evaluation. A randomized, controlled, blind-observer, multicenter phase III study. Disease progression in scleroderma.
MedDRA version: 6.1;Level: HLT;Classification code 10039711
Trade Name: ENDOPROST 0,05MG/0,5ML 1F
INN or Proposed INN: iloprost trometamol
ITALFARMACONULLNot RecruitingFemale: yes
Male: yes
69Phase 3Italy